Additional financial information-Grünenthal deal

31 October 2018 09:45 GMT

Additional financial information in respect of the previously-
announced agreement with Grünenthal for rights to
Nexium in Europe and Vimovo worldwide (ex-US)

Pursuant to Listing Rule 10.4.1R (notification of class 2 transactions), AstraZeneca provides the following additional financial information in respect of the previously-announced agreement with Grünenthal for rights to Nexium in Europe and Vimovo worldwide (ex-US). The announcement of the agreement was initially released at 07:00 GMT on 30 October 2018.

The book value of gross assets subject to the divestments was approximately $99 million at 31 December 2017. In the year to 31 December 2017 the aggregate pre-tax profits attributable to Nexium and Vimovo in the relevant territories were $203 million. The consideration will be satisfied in cash and the proceeds used for general corporate purposes.

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.

Adrian Kemp

Company Secretary

AstraZeneca PLC